Comparative Pharmacology
Head-to-head clinical analysis: ADREVIEW versus PORCINE SECRETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADREVIEW versus PORCINE SECRETIN.
ADREVIEW vs PORCINE SECRETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADREVIEW is a beta-2 adrenergic receptor agonist that stimulates cyclic AMP production, leading to bronchodilation and inhibition of mast cell mediator release.
Stimulates exocrine pancreatic secretion by acting on secretin receptors on pancreatic ductal cells, increasing bicarbonate and water secretion. Also stimulates bile and gastric acid secretion.
0.5 mg intramuscularly every 20 minutes as needed, up to 3 doses, for acute allergic reactions; or 0.1-0.5 mg subcutaneously for bronchospasm.
0.2 mcg/kg intravenous bolus over 1 minute, maximum 20 mcg.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours; clinically relevant for dosing every 4-6 hours in renal impairment.
The terminal elimination half-life is approximately 4-6 minutes, reflecting rapid degradation by plasma proteases; this short half-life limits its systemic duration of action and necessitates continuous infusion for sustained secretory testing.
Primarily renal (80-90% as unchanged drug), with minor biliary/fecal elimination (<10%).
Primarily renal, with over 90% of the administered dose eliminated via glomerular filtration and tubular reabsorption; fecal and biliary excretion are negligible.
Category C
Category C
Diagnostic Agent
Diagnostic Agent